510 related articles for article (PubMed ID: 29374065)
1. Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.
Li L; Wang L; Li J; Fan Z; Yang L; Zhang Z; Zhang C; Yue D; Qin G; Zhang T; Li F; Chen X; Ping Y; Wang D; Gao Q; He Q; Huang L; Li H; Huang J; Zhao X; Xue W; Sun Z; Lu J; Yu JJ; Zhao J; Zhang B; Zhang Y
Cancer Res; 2018 Apr; 78(7):1779-1791. PubMed ID: 29374065
[TBL] [Abstract][Full Text] [Related]
2. Autocrine Adenosine Regulates Tumor Polyfunctional CD73
Gourdin N; Bossennec M; Rodriguez C; Vigano S; Machon C; Jandus C; Bauché D; Faget J; Durand I; Chopin N; Tredan O; Marie JC; Dubois B; Guitton J; Romero P; Caux C; Ménétrier-Caux C
Cancer Res; 2018 Jul; 78(13):3604-3618. PubMed ID: 29559470
[TBL] [Abstract][Full Text] [Related]
3. High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer.
Bareche Y; Pommey S; Carneiro M; Buisseret L; Cousineau I; Thebault P; Chrobak P; Communal L; Allard D; Robson SC; Mes-Masson AM; Provencher D; Lapointe R; Stagg J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33771891
[TBL] [Abstract][Full Text] [Related]
4. Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity.
Häusler SF; Montalbán del Barrio I; Strohschein J; Chandran PA; Engel JB; Hönig A; Ossadnik M; Horn E; Fischer B; Krockenberger M; Heuer S; Seida AA; Junker M; Kneitz H; Kloor D; Klotz KN; Dietl J; Wischhusen J
Cancer Immunol Immunother; 2011 Oct; 60(10):1405-18. PubMed ID: 21638125
[TBL] [Abstract][Full Text] [Related]
5. Phenotypical analysis of ectoenzymes CD39/CD73 and adenosine receptor 2A in CD4
Han L; Sugiyama H; Zhang Q; Yan K; Fang X; McCormick TS; Cooper KD; Huang Q
Australas J Dermatol; 2018 Feb; 59(1):e31-e38. PubMed ID: 28295154
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD73 and A2A receptors in cells from subjects with obesity and type 2 diabetes mellitus.
Guzman-Flores JM; Cortez-Espinosa N; Cortés-Garcia JD; Vargas-Morales JM; Cataño-Cañizalez YG; Rodríguez-Rivera JG; Portales-Perez DP
Immunobiology; 2015 Aug; 220(8):976-84. PubMed ID: 25770019
[TBL] [Abstract][Full Text] [Related]
7. Defining the CD39/CD73 Axis in SARS-CoV-2 Infection: The CD73
Ahmadi P; Hartjen P; Kohsar M; Kummer S; Schmiedel S; Bockmann JH; Fathi A; Huber S; Haag F; Schulze Zur Wiesch J
Cells; 2020 Jul; 9(8):. PubMed ID: 32707842
[TBL] [Abstract][Full Text] [Related]
8. CD73 is associated with poor prognosis in high-grade serous ovarian cancer.
Turcotte M; Spring K; Pommey S; Chouinard G; Cousineau I; George J; Chen GM; Gendoo DM; Haibe-Kains B; Karn T; Rahimi K; Le Page C; Provencher D; Mes-Masson AM; Stagg J
Cancer Res; 2015 Nov; 75(21):4494-503. PubMed ID: 26363007
[TBL] [Abstract][Full Text] [Related]
9. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.
Xu S; Shao QQ; Sun JT; Yang N; Xie Q; Wang DH; Huang QB; Huang B; Wang XY; Li XG; Qu X
Neuro Oncol; 2013 Sep; 15(9):1160-72. PubMed ID: 23737488
[TBL] [Abstract][Full Text] [Related]
10. Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.
Covarrubias R; Chepurko E; Reynolds A; Huttinger ZM; Huttinger R; Stanfill K; Wheeler DG; Novitskaya T; Robson SC; Dwyer KM; Cowan PJ; Gumina RJ
Arterioscler Thromb Vasc Biol; 2016 Sep; 36(9):1809-20. PubMed ID: 27417582
[TBL] [Abstract][Full Text] [Related]
11. Adenosine and the adenosine A2A receptor agonist, CGS21680, upregulate CD39 and CD73 expression through E2F-1 and CREB in regulatory T cells isolated from septic mice.
Bao R; Shui X; Hou J; Li J; Deng X; Zhu X; Yang T
Int J Mol Med; 2016 Sep; 38(3):969-75. PubMed ID: 27430240
[TBL] [Abstract][Full Text] [Related]
12. CD39 and CD73 in the aortic valve-biochemical and immunohistochemical analysis in valve cell populations and its changes in valve mineralization.
Kaniewska-Bednarczuk E; Kutryb-Zajac B; Sarathchandra P; Pelikant-Malecka I; Sielicka A; Piotrowska I; Slominska EM; Chester AH; Yacoub MH; Smolenski RT
Cardiovasc Pathol; 2018; 36():53-63. PubMed ID: 30056298
[TBL] [Abstract][Full Text] [Related]
13. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia.
Pulte D; Furman RR; Broekman MJ; Drosopoulos JH; Ballard HS; Olson KE; Kizer JR; Marcus AJ
Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):367-72. PubMed ID: 21816376
[TBL] [Abstract][Full Text] [Related]
14. Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways.
Giatromanolaki A; Kouroupi M; Pouliliou S; Mitrakas A; Hasan F; Pappa A; Koukourakis MI
Life Sci; 2020 Oct; 259():118389. PubMed ID: 32898522
[TBL] [Abstract][Full Text] [Related]
15. Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways.
Morianos I; Trochoutsou AI; Papadopoulou G; Semitekolou M; Banos A; Konstantopoulos D; Manousopoulou A; Kapasa M; Wei P; Lomenick B; Belaidi E; Kalamatas T; Karageorgiou K; Doskas T; Sallusto F; Pan F; Garbis SD; Quintana FJ; Xanthou G
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12269-12280. PubMed ID: 32409602
[TBL] [Abstract][Full Text] [Related]
16. CD73 Inhibits cGAS-STING and Cooperates with CD39 to Promote Pancreatic Cancer.
Jacoberger-Foissac C; Cousineau I; Bareche Y; Allard D; Chrobak P; Allard B; Pommey S; Messaoudi N; McNicoll Y; Soucy G; Koseoglu S; Masia R; Lake AC; Seo H; Eeles CB; Rohatgi N; Robson SC; Turcotte S; Haibe-Kains B; Stagg J
Cancer Immunol Res; 2023 Jan; 11(1):56-71. PubMed ID: 36409930
[TBL] [Abstract][Full Text] [Related]
17. Target tissue ectoenzyme CD39/CD73-expressing Foxp3+ regulatory T cells in patients with psoriasis.
Zhang HY; Yan KX; Huang Q; Ma Y; Fang X; Han L
Clin Exp Dermatol; 2015 Mar; 40(2):182-91. PubMed ID: 25284153
[TBL] [Abstract][Full Text] [Related]
18. Oxidized low-density lipoproteins enhance expression and activity of CD39 and CD73 in the human aortic valve endothelium.
Kaniewska-Bednarczuk E; Mielcarek M; Chester AH; Slominska EM; Yacoub MH; Smolenski RT
Nucleosides Nucleotides Nucleic Acids; 2016 Dec; 35(10-12):713-719. PubMed ID: 27906627
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological blockade of the CD39/CD73 pathway but not adenosine receptors augments disease in a humanized mouse model of graft-versus-host disease.
Geraghty NJ; Watson D; Sluyter R
Immunol Cell Biol; 2019 Jul; 97(6):597-610. PubMed ID: 30957314
[TBL] [Abstract][Full Text] [Related]
20. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression.
Deaglio S; Dwyer KM; Gao W; Friedman D; Usheva A; Erat A; Chen JF; Enjyoji K; Linden J; Oukka M; Kuchroo VK; Strom TB; Robson SC
J Exp Med; 2007 Jun; 204(6):1257-65. PubMed ID: 17502665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]